An open label, randomised, muliticentre Phase III Trial of Dasatnib (SPRYCEL®) vs standard dose Imatininb (400mg) in the treatment of subjects with newly diagnosed chronic phase Philadelphia chromosome positive chronic myeloid leukaemia (CML).

Published: 22-06-2007
Last updated: 08-05-2024

To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib

Ethical review	Approved WMO
Status	Pending
Health condition type	Leukaemias
Study type	Interventional

Summary

ID

NL-OMON31003

Source
ToetsingOnline

Brief title
CA180-056

Condition

- Leukaemias

Synonym
Chronic Myeloid Leukemia

Research involving
Human

Sponsors and support

Primary sponsor: Bristol-Myers Squibb
Source(s) of monetary or material Support: Farmaceutische Industrie

Intervention

Keyword: Dasatinib, Imatinib, Leukaemia, Randomised

Outcome measures

Primary outcome

To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib

Secondary outcome

To compare different efficacy parameters within 12 months: major molecular response rate, major cytogenetic response rate and complete haematologic response.

To compare different study parameters within 12 months: best response rates ,duration of the different responses, progression free survival and time to treatment failure.

To explore the toxicity profile for each treatment arm.

To explore the development of BCR-ABL gene mutations in each treatment arm.

Study description

Background summary

Imatinib is the current approved standard treatment for newly diagnosed CML. However, Dasatinib has also been shown to be efficacious in subjects resistant and intolerant to imatinib and has been approved by the FDA for treatment in this setting. In an ongoing phase II trial in chronic phase CML subjects that are treatment naïve, Dasatinib has been shown to produce rapid and positive complete cytogenetic response rates. It is important to confirm these initial results in a Phase III comparative trial. If the results from this trial are positive for Dasatinib, it would provide improved treatment options for this sub-set of CML patients.

Study objective

To compare the best confirmed complete cytogenetic response (CCyR) rates within 12 months in newly diagnosed chronic phase CML subjects treated with dasatinib versus imatinib

Study design

Open label, subjects will be randomised to receive either Imatinib or dasatinib. Randomisation will be stratified by Hasford score (refer to protocol) and prior imatinib.

Intervention

Either dastanib (400mg QD) or imatinib (100mg QD), both orally administered.

Study burden and risks

Patients will be subject to invasive procedures (blood and bone marrow sampling) but these procedures will be performed by trained medical staff so any risks or pain associated with these procedures should be minimised. The most commonly reported toxicities from either drug treatment is myelosuppression and those as listed in section E9, some of which can be severe in nature. However, patients will be followed closely for toxicities and appropriate medical care given and based on previous human studies these toxicities are manageable.

Contacts

Public
Bristol-Myers Squibb

Vijzelmolenlaan 9
3440 AM Woerden

NL
Scientific
Bristol-Myers Squibb

Vijzelmolenlaan 9
3440 AM Woerden
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

- Subjects must have Philadephia Chromosome positive CML as defined in section 4.2.1 point 2 of the protocol.
- Subjects must be previously untreated for chronic CML (however less than 28 days of prior treatment with imatinib is allowed, refer to 4.2.1 point 3)
- Subjects must be enrolled within 90 days of diagnosis of CML, based on cytogenetic testing confirming the presence of the Philadephia Chromosome.
- ECOG performance status score 0-2
- Adequate hepatic function-refer to protocol section 4.2.1 point 6 for hepatic parameters that need to be met.
- Adequate renal function-refer to protocol section 4.2.1 point 7.
- Aged 18 years +
-Women of child bearing potential (WOCBP) are to use an adequate contraception 4 weeks before the study, throughout the study and for at least 4 weeks after discontinuing from the study.
- WOCBP must have a negative serum or urine pregnancy test within 72 hours of the start of the study drug.

Exclusion criteria

-WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy 4 weeks before the study, throughout the study and for at least 4 weeks after discontinuing from the study.
-Women who are pregnant or breastfeeding
-Women with a positive pregnancy test at enrolment or prior to study treatment
- Men whose sexual partners are WOCBP who are unwilling or unable to use an accepted method of contraception throughout the study and for at least 4 weeks after discontinuing from the study.
- A serious uncontrolled medical disorder or active infection
- Known pleural effusion at baseline
- Uncontrolled or significant heart disease (see section 4.2.2 point 8 for examples)
- History of any significant bleeding disorder unrelated to CML (see section 4.2.2 point 9 for examples).
- Prior chemotherapy for peripheral stem mobilisation
- Prior of concurrent malignancy (see exceptions in section 4.2.2 point 11)
- Evidence of digestive dysfunction that would prevent oral administration of study drug.
- Any prior treatment with interferon
- Any prior treatment with dasatinib
- Any other prior systemic treatments with anti- CML activity (see exceptions in section 4.2.2 point 15)
- Subjects currently taking drugs that are generally accepted to have a risk of causing Torsades de Pointes, refer to section 5.5.1 of the protocol.
- Prisoners or subjects who are compulsory detained for treatment of either a psychiatric or physical illness must not be enrolled.

Study design

Design

Study phase:	3
Study type:	Interventional
Intervention model:	Parallel
Allocation:	Randomized controlled trial
Masking:	Open (masking not used)
Control:	Active
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-11-2007
Enrollment:	5
Type:	Anticipated

Medical products/devices used

Product type:	Medicine
Brand name:	Gleevec
Generic name:	Imatinib
Registration:	Yes - NL intended use
Product type:	Medicine
Brand name:	Sprycel
Generic name:	Dasatinib
Registration:	Yes - NL outside intended use

Ethics review

Approved WMO Date:	22-06-2007
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	15-11-2007
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	09-01-2008
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	18-02-2008
Application type:	Amendment

Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	27-05-2008
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	13-08-2008
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	13-01-2009
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	25-03-2009
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	10-06-2009
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	06-10-2009
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	09-02-2010
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	16-08-2010
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	13-12-2011
Application type:	Amendment

Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	24-06-2013
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	23-08-2013
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO Date:	09-12-2013
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
Other	Clintrials.gov and the identifier number is NCT00481247.
EudraCT	EUCTR2006-005712-27-NL
CCMO	NL18134.091.07